(NASDAQ: AMGN) Amgen's forecast annual revenue growth rate of 5.51% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.76%.
Amgen's revenue in 2024 is $29,532,000,000.On average, 10 Wall Street analysts forecast AMGN's revenue for 2024 to be $17,700,717,829,579, with the lowest AMGN revenue forecast at $17,475,432,961,284, and the highest AMGN revenue forecast at $17,827,334,119,236. On average, 11 Wall Street analysts forecast AMGN's revenue for 2025 to be $18,242,676,726,037, with the lowest AMGN revenue forecast at $17,767,789,868,424, and the highest AMGN revenue forecast at $18,721,493,504,204.
In 2026, AMGN is forecast to generate $18,568,067,281,511 in revenue, with the lowest revenue forecast at $17,141,770,582,860 and the highest revenue forecast at $19,481,153,155,282.